In the Phase 2a trial, all three dosages of CCH , mid and high ) showed a noticable difference in the looks of cellulite as measured by the trial endpoints of an investigator and an individual score in the Global Aesthetic Improvement Scale , that was adapted by the business for use in cellulite. The mid and high dose organizations demonstrated a statistically significant improvement in the looks of cellulite, as measured by GAIS ratings, with a p-worth of <0.05 in comparison to placebo for both endpoints. In the mid and high dosage organizations, 68 % of sufferers reported being 'Pleased' or 'Extremely Satisfied' with the outcomes of their treatment, in comparison to just 34 % of sufferers randomized to placebo.announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral medication candidate discovered by Arena that targets the histamine H3 receptor for the treating narcolepsy and cataplexy. There is a need for better tolerated, far better therapies for narcolepsy, narcolepsy with cataplexy especially, said William R. Shanahan, M.D., Arena’s Vice President and Chief Medical Officer. Based on preclinical data, we think that APD916 may substantially improve the treatment of these potential orphan indications.